Tunicamycin | Enzo Life Sciences BML-CC104-0010 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

Tunicamycin

catalog :

BML-CC104-0010

quantity :

10 mg

citations: 11

Reference
Law C, Ashcroft H, Zheng W, Sexton J. Assay development and multivariate scoring for high-content discovery of chemoprotectants of endoplasmic-reticulum-stress-mediated amylin-induced cytotoxicity in pancreatic beta cells. Assay Drug Dev Technol. 2014;12:375-84 pubmed publisher
Shenderov K, Riteau N, Yip R, Mayer Barber K, Oland S, Hieny S, et al. Cutting edge: Endoplasmic reticulum stress licenses macrophages to produce mature IL-1? in response to TLR4 stimulation through a caspase-8- and TRIF-dependent pathway. J Immunol. 2014;192:2029-2033 pubmed publisher
Yoshida T, Shiraishi T, Horinaka M, Wakada M, Sakai T. Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. Oncol Rep. 2007;18:1239-42 pubmed
Jiang C, Chen L, Gillespie S, Kiejda K, Mhaidat N, Wang Y, et al. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 2007;67:5880-8 pubmed
Horikawa K, Oishi N, Nakagawa J, Kasai A, Hayakawa K, Hiramatsu N, et al. Novel potential of tunicamycin as an activator of the aryl hydrocarbon receptor -- dioxin responsive element signaling pathway. FEBS Lett. 2006;580:3721-5 pubmed
Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 2005;65:6364-70 pubmed
Maruo K, Nagata T, Yamamoto S, Nagai K, Yajima Y, Maruo S, et al. Tunicamycin inhibits NMDA and AMPA receptor responses independently of N-glycosylation. Brain Res. 2003;977:294-7 pubmed
Matherly L, Angeles S. Role of N-glycosylation in the structure and function of the methotrexate membrane transporter from CCRF-CEM human lymphoblastic leukemia cells. Biochem Pharmacol. 1994;47:1094-8 pubmed
Tordai A, Brass L, Gelfand E. Tunicamycin inhibits the expression of functional thrombin receptors on human T-lymphoblastoid cells. Biochem Biophys Res Commun. 1995;206:857-62 pubmed
Mahoney W, Duksin D. Separation of tunicamycin homologues by reversed-phase high-performance liquid chromatography. J Chromatogr. 1980;198:506-10 pubmed
Duksin D, Mahoney W. Relationship of the structure and biological activity of the natural homologues of tunicamycin. J Biol Chem. 1982;257:3105-9 pubmed

product information

Product ID :

BML-CC104

Catalog Number :

BML-CC104-0010

Product Name :

Tunicamycin

Product Type :

Biochemical

Size :

10 mg

list of Pubmed id :

24489101, 17914579, 17575157, 16765953, 16024639, 12834891, 8147910, 7832797, 7440684, 7061468

Product Description :

Nucleoside antibiotic. Inhibits protein N-glycosylation by blocking the transfer of N-acetylglucosamine 1-phosphate to dolichol monophosphate. Induces ER-stress following the inhibition of N-linked glycosylation. Arrests cell cycle in late G1. Unstable at acidic pH.

Purity :

≥99% (TLC)

Storage :

-20°C